Alzheimer’s Disease (AD) research and clinical trials rely heavily on a range of cognitive assessment tools to measure disease progression and treatment efficacy. This guide provides a review of the most widely used scales in AD drug development, ADAS-Cog, CDR, FCSRT, Functional Assessment Scales, MMSE, MoCA, and Verbal List Learning tests.
Each scale offers unique advantages and faces specific challenges in its application, making it essential to understand their nuances as clinical trial teams consider study endpoint selection.
The information shared here is based on interviews and inputs from key Alzheimer’s disease science leadership at Cogstate who have decades of experience administering, reviewing, and utilizing these scales within industry clinical trials.
Authors:
- Kaycee Sink, MD (Chief Medical Officer)
- Svenja Wacker, PhD (Neuropsychology Science Director)
- Annamarie Vogt, PhD (Scientific Consulting Lead)
Please fill out the form below to access the fact sheet and learn more.
